Phase i study of nelfinavir in liposarcoma

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 6, 2012, Pages 791-799

  Pan, Janet ^a   Mott, Michelle ^a   Xi, Bixin ^b   Hepner, Ernestine ^a   Guan, Min ^b   Fousek, Kristen ^b   Magnusson, Rachel ^a   Tinsley, Raechelle ^c   Valdes, Frances ^d   Frankel, Paul ^a   Synold, Timothy ^b   Chow, Warren A ^a,b  

^a City of Hope ^*  (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c Clinical Trials Office   (United States)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

Liposarcoma; Nelfinavir; Pharmacokinetics; Phase I

Indexed keywords

DRUG METABOLITE; M 8; NELFINAVIR; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BICARBONATE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOXIA; LEUKOCYTE COUNT; LIPOSARCOMA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; PAIN; PANCREATITIS; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPOSARCOMA; MALE; MIDDLE AGED; NELFINAVIR; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84871201547     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1961-4     Document Type: Article

References (32)

1. Fletcher CDM, Rydholm A, Singer S, Sudaram M, Coindre JM (2002) Soft tissue tumours: epidemiology, clinical features, histopathological typing and grading. In: Fletcher CDM, Unni KK, Mertens F (eds) Pathology & genetics: tumours of soft tissue and bone. IARC Press, Lyon, pp 9-19
2. Flexner C (1998) HIV-protease inhibitors. N Engl J Med 338: 1281-1292
3. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidemia, and diabetes mellitus. Lancet 353:2093-2099
4. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD et al (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients. JAMA 29(2):191-201
5. Brinkman K,Smeitink JA,Romjin JA, Reiss P (1999)Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy- related lipodystrophy. Lancet 354:1112-1115
6. Caron M, Auclair M, Vigourox C, Glorian M, Forest C, Capeau J (2001) The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50:1378-1388
7. Nguyen AT, Gagnon AM, Angel JB, Sorisky A (2000) Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. AIDS 14:2467-2473
8. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C et al (2002) Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1- infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359:1026-1031
9. Brown MS, Goldstein JL (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331-340
10. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS (1997) Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 99:838-845
11. Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME et al (2004) Dysregulation of sterol response elementbinding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 64: 2212-2221
12. Sakai J, Nohturfft A, Goldstein JL, Brown MS (1998) Cleavage of sterol regulatory element-binding proteins (SREBPs) at stie-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. J Biol Chem 273: 5785-5793
13. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R et al (2002) Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 110:489-500
14. Brown MS, Ye J, Rawson RB, Goldstein JL (2000) Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100:391-398
15. Guan M, Fousek K, Jiang C, Guo S, Synold T, Xi B et al (2011) Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6. Clin Cancer Res 17:1796-1806
16. Chow WA, Guo S, Valdes-Albini F (2006) Nelfinavir induces liposarcoma apoptosis and cell-cycle arrest by upregulating sterol regulatory element binding protein-1. Anticancer Drugs 17:891-903
17. Von Hoff D, Kuhn J, Clark GM (1985) Design and conduct of phase I trials. In: Buyse ME, Staquet MJ, Sylvester RJ (eds) Cancer clinical trials: methods and practice. Oxford University Press, Oxford
18. Therasse P, Arbuck S, Eisenhauser E, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92:205-216
19. Di Martino V, Ezenfis J, Benahmou Y, Bernard B, Opolon P, Bricaire F et al (1999) Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge. AIDS 13:1421
20. Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV et al (1998) Characterisation of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 26:609-616
21. Merry C, Barry M, Ryan M, Gibbons S, Tijia J, Mulcahy F, Back D. A study of the pharmacokinetics of repetitive dosing with nelfinavir. 7th European Conference on Clinical Aspects and Treatment of HIV Infection, 1999, Abstract 831
22. Burton ME, Shaw LM, Schentag JJ, Evans WE (2006) Applied pharmacokinetics & pharmacodynamics principles of therapeutic drug monitoring. Lippincott Williams & Wilkins, USA
23. Jones RL, Fisher C, Al-Muderis O, Judson IR (2005) Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 41:2853-2860
24. Gupta AK, Lin G, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A (2007) The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia 9:271-278
25. Jiang Z, Pore N, Cerniglia GJ, Mick R, Georgescu MM, Bernhard EJ et al (2007) Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 67:4467-4472
26. Yang Y, Ikezoe T, Takeuchi T, Adachi Y, Ohtsuki Y, Takeuchi S et al (2005) HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci 96:425-433
27. Pyrko P, Kardosh A, Wang W, Xiong W, Schonthal AH, Chen TC (2007) HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res 67:10920-10928
28. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu- Asab MS, et al. (2007) Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 13, 5183-5194
29. http://clinicaltrials.gov/ct2/results?term=nelfinavir?cancer. Accessed February 14, 2012
30. Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A et al (2008) A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 26:2699-2706
31. De La Garza GO, Ismail AF, Anderson CM, Werner WW, Mihem MM, Hoffman HT et al (2011) Nelfinavir treatment of adenoid cystic carcinoma. A case report, Practical Radiation Oncol
32. Chow WA, Jiang C, Guan M (2009) Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 10:61-71